On Friday, Shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA), gained 4.53% to $2.54.
Idera Pharmaceuticals stated its financial and operational results for the second quarter ended June 30, 2015.
Research and Development Program Updates
Toll-like Receptor (TLR) Agonism Program
Immuno-Oncology Program
In June 2015, the company declared that it had reached a planned clinical research alliance with MD Anderson Cancer Center to advance the clinical development of intratumoral TLR9 agonists in combination with checkpoint inhibitors. The company also declared that it anticipates to initiate the first trial from the alliance, a Phase 1/2 study to assess the safety and efficacy of intratumoral IMO-2125 in combination with ipilimumab in about 45 patients with metastatic melanoma. The company intends to initiate this study in the fourth quarter of 2015 with data predictable in 2016. Planning of additional studies as part of the clinical research alliance with MD Anderson Cancer Center is in progress. Additionally, the company recently has had two abstracts accepted with new pre-clinical data on intratumoral IMO-2125 activity, and its impact on the tumor microenvironment and checkpoints at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference taking place in September in New York.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States.
Shares of Kite Pharma Inc (NASDAQ:KITE), declined -1.49% to $50.28, during its last trading session.
Kite Pharma, offered an update from the Company’s ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin’s lymphoma (NHL) who have failed preceding chemotherapy treatments and have a poor prognosis. KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.
In May, Kite declared that the first patient was treated with KTE-C19 in the Phase 1 portion of the trial and we have since treated multiple patients. Complete responses have been observed by investigators. The responses happened shortly after treatment was administered and Kite is monitoring these patients to determine durability of treatment. To date, toxicities associated with treatment have been similar to those observed in the National Cancer Institute’s study of anti-CD19 CAR T cell therapy. There was one patient death early in the study, which was determined to be unrelated to KTE-C19 by the study investigator. After appropriate talk aboutions with the U.S. Food and Drug Administration (FDA), Kite continued to enroll and treat patients in its study and the study was never placed on clinical hold. Kite has presented an abstract and plans to present top-line data from the Phase 1 portion of the trial at the forthcoming 2015 American Society of Hematology (ASH) Annual Meeting, to take place in Orlando, FL, December 5-8, 2015.
“We are encouraged by the progress of the KTE-C19 clinical trial and excited by the responses we have seen so far. We believe the KTE-C19 clinical findings are in line with previous results demonstrating the potential of this promising therapeutic approach,” said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. “In agreement with ASH, we have taken this exceptional step of providing an update on the trial in order to address recent misinformation in the market related to our clinical program. We are on track to transition to the Phase 2 portion of the trial and plan to present Phase 1 data at ASH later this year.”
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
At the end of Friday’s trade, Shares of Two Harbors Investment Corp (NYSE:TWO), lost -2.22% to $9.67.
Two Harbors Investment Corp., declared the appointment of Jeffrey Hurley as Managing Director and Chief Technology Officer. Mr. Hurley has over 25 years of experience in technology administration and has held leadership positions with Canada Pension Plan Investment Board, Nomura Holdings and various Fortune 500 companies counting The Walt Disney Company, Cendant, H&R Block and Lehman Brothers.
“We are happy to declare Jeff’s appointment as Managing Director and Chief Technology Officer,” stated Thomas Siering, Two Harbors’ President and Chief Executive Officer. “Jeff’s breadth of experience will be instrumental in growing our technology resources in support of the ongoing expansion of our business.”
Preceding to joining the company, Mr. Hurley served as Managing Director, Head of Technology, at the Canada Pension Plan Investment Board since 2011. In this role, Mr. Hurley was responsible for leading the Information Technology department, working with Capital Markets, Private Investments and Real Estate teams in Toronto, New York, London, Hong Kong and San Paulo. From 2004 to 2011, Mr. Hurley served as an Executive Director, Fixed Income Technology at Nomura Holdings. Preceding to his time at Nomura Holdings, Mr. Hurley served in a variety of leadership roles with various Fortune 500 companies, counting The Walt Disney Company, Cendant, H&R Block and Lehman Brothers. Mr. Hurley holds a B.A. in Business Administration Finance from California State University, Fullerton, and an M.B.A. from the Marshall School of Business at University of Southern California.
Two Harbors Investment Corp. operates as a real estate investment trust (REIT) that focuses on investing in, financing, and managing residential mortgage-backed securities (RMBS), residential mortgage loans, mortgage servicing rights, commercial real estate debt and related assets, and other financial assets.
Finally, Live Nation Entertainment, Inc. (NYSE:LYV), ended its last trade with -3.94% loss, and closed at $24.38.
Live Nation Entertainment and Revention declared a new multi-year naming rights deal to the premier indoor music theater located in downtown Houston. The new venue name is Revention Music Center.
Through artist meet and greets, access to the VIP club and the ability to make tickets accessible for events at the theater, Revention employees will join in on the thrill of being up close to the live music experience. A custom renovation of the venue space is in progress, with a new viewing area being designed, to be called The Revention Suite. The Revention brand will be fully integrated across the venue, counting with the installation of Revention point-of-sale technology and equipment within the theater.
“We look forward to working with a great Houston company like Revention,” said Drew Dixon, general manager, Revention Music Center. “It is such a great opportunity to showcase their point-of-sale technology in our venue, while taking advantage of the great talent and shows, VIP hospitality, and live music experience Revention Music Center delivers to entertain Revention’s clients and employees.”
Live Nation Entertainment, Inc. operates as a live entertainment company. The company operates through Concerts, Ticketing, Artist Nation, and Sponsorship & Advertising segments. The Concerts segment promotes live music events in its owned and/or operated venues, and in rented third-party venues; operates and manages music venues; and produces music festivals.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
